Intra-Biotech Consolidation in Europe? Not Affordable.

Bankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.

Bankers and consultants have long been urging the virtues of consolidation onto a financially strapped biotech industry. But few companies on either side of the Atlantic have been listening.

Tracking intra-European dealmaking by type of acquirer and target, Windhover's Strategic Transactions Database shows that overall dealmaking has declined, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo